Get the Stockscreener App
4.88
3.56%
-0.18
After Hours:
4.92
0.04
+0.82%
Exscientia Plc Adr stock is traded at $4.88, with a volume of 619.92K.
It is down -3.56% in the last 24 hours and down -12.23% over the past month.
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe, and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.
See More
Previous Close:
$5.06
Open:
$5
24h Volume:
619.92K
Relative Volume:
0.94
Market Cap:
$642.71M
Revenue:
$25.81M
Net Income/Loss:
$-188.12M
P/E Ratio:
-3.3648
EPS:
-1.4503
Net Cash Flow:
$-183.77M
1W Performance:
-3.17%
1M Performance:
-12.23%
6M Performance:
-14.69%
1Y Performance:
+7.96%
1-Day Range:
$4.825
$5.14
1-Week Range:
$4.825
$5.42
52-Week Range:
$3.80
$7.91
Exscientia Plc Adr Stock (EXAI) Company Profile
Exscientia Plc Adr Stock (EXAI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-24 | Downgrade | BofA Securities | Buy → Neutral |
Exscientia Plc Adr Stock (EXAI) Latest News
Exscientia Plc ADR (EXAI)’s Market Momentum: Closing Strong at 5.06, Down -4.53 - The Dwinnex
Taking on analysts’ expectations and winning: Exscientia Plc ADR (EXAI) - SETE News
Exscientia's SWOT analysis: AI biotech stock faces merger, pipeline milestones - Investing.com
Exscientia Plc ADR (EXAI) expanding its growth trajectory ahead - SETE News
A stock that deserves closer examination: Exscientia Plc ADR (EXAI) - US Post News
Take off with Exscientia Plc ADR (EXAI): Get ready for trading - SETE News
Exscientia Plc ADR (EXAI)’s stock chart: A technical perspective - US Post News
Market Insights: Exscientia Plc ADR (EXAI)’s Notable Gain of 3.78, Closing at 5.22 - The Dwinnex
EXAI’s 52-Week Rollercoaster: From $3.80 to $7.91 – What’s Next for Investors? - The InvestChronicle
Closing Figures Unveiled: Exscientia Plc ADR (EXAI) Drop -1.02, Closes at 4.85 - The Dwinnex
EXAI (Exscientia Plc ADR) has impressive results - US Post News
Check out these key findings about Exscientia Plc ADR (EXAI) - SETE News
Exscientia Plc ADR (EXAI) Stock: A Year of Market Fluctuations - The InvestChronicle
Are Investors Keen On Selling Holdings In N2OFF Inc. (NASDAQ: NITO)? - Stocks Register
Daily Market Movement: Exscientia Plc ADR (EXAI) Sees a -1.77 Decrease, Closing at 5.56 - The Dwinnex
Ratios Reveal: Breaking Down Exscientia Plc ADR (EXAI)’s Financial Health - The Dwinnex
AI in Pharma and Biotech Market Projected Growth at 18.8% CAGR to Reach USD 13.1 billion by 2034 | Exclusive Research Report by Transparency Market Research Inc. - GlobeNewswire Inc.
Exscientia to Present at the Morgan Stanley 22 nd Annual Global Healthcare Conference - TT Nyhetsbyrån
Recursion Pharmaceuticals secures key shareholder support - Investing.com
What technical indicators reveal about EXAI stock - US Post News
Deeper Dive: Understanding Exscientia Plc ADR (EXAI) Through its Various Ratios - The Dwinnex
Have you been able to find a good deal on Exscientia Plc ADR’s shares? - US Post News
The Bull Thesis for Recursion Pharmaceuticals Stock Just Got Stronger. Here's Why. - The Motley Fool
Exscientia Plc ADR (EXAI) Is Worth Accumulating At Current Levels - Stocks Register
EXAI’s Stock Market Puzzle: Piecing Together 2023’s Performance - The InvestChronicle
Market Resilience: Exscientia Plc ADR (EXAI) Finishes Strong at 5.00, Up 2.88 - The Dwinnex
Taking the lead: Exscientia Plc ADR (EXAI) - SETE News
Examining Exscientia Plc ADR (EXAI) stock is warranted - US Post News
Before Buying Exscientia Plc ADR (NASDAQ: EXAI) Stock, Read This First - Stocks Register
Exscientia stock downgraded to Hold amid Recursion merger - Investing.com
Recursion and Exscientia announce merger to enhance drug discovery - Investing.com
Recursion and Exscientia announce merger to enhance drug discovery - Investing.com India
Views of Wall Street’s Leading Experts on Exscientia Plc ADR - SETE News
EXAI’s Debt-to-Equity Ratio at 0.06: What It Means for Exscientia Plc ADR’s Future - The InvestChronicle
Amazon (AMZN) Plunges 19.1% in a Month: Should You Buy the Dip? - Zacks Investment Research
Market Momentum: Exscientia Plc ADR (EXAI) Registers a -8.19 Decrease, Closing at 4.26 - The Dwinnex
Analyzing the Impact of Earnings Reports on Vivid Seats Inc Inc. (SEAT) Price Performance - The InvestChronicle
Exscientia Plc ADR (EXAI) Stock: Navigating Market Highs and Lows in 52 Weeks - The InvestChronicle
A Deep Dive into Clear Channel Outdoor Holdings Inc. (CCO) Stock Performance - The InvestChronicle
Investor’s Toolkit: Key Ratios for Assessing Exscientia Plc ADR (EXAI)’s Performance - The Dwinnex
How to interpret Exscientia Plc ADR (EXAI)’s stock chart patterns - US Post News
Balance Sheet Insights: Exscientia Plc ADR (EXAI)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Exscientia gets buy rating, positive on asset control and trial plans - Investing.com
Exscientia takes full control of cancer drug program - Investing.com
The Exscientia Plc ADR (EXAI) had a good session last reading, didn’t it? - US Post News
This trade activity should not be overlooked: Exscientia Plc ADR (EXAI) - SETE News
Amazon (AMZN) Expands AWS Clientele With Exscientia Deal - Yahoo Finance
Financial Analysis: Exscientia Plc ADR (EXAI)’s Ratios Unveil Key Insights - The Dwinnex
Exscientia Plc ADR: Weathering Stock Market Storms with 702.17M Market Cap - The InvestChronicle
AWS says it has trained millions of workers on key cloud skills for free - Yahoo Singapore News
Exscientia expands AI drug discovery with AWS - Investing.com
Exscientia Plc Adr Stock (EXAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):